| Summary of subsidiaries, VIE and VIE's subsidiaries |
As of December 31, 2025, the Company’s principal subsidiaries, VIE and VIE’s subsidiaries are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
of legal ownership
by the Company |
|
|
Principal
activities |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BR Hong Kong Limited |
|
|
April 1, 2014 |
|
|
|
Hong Kong |
|
|
|
100 |
% |
|
Investment holding |
| Guangzhou Burning Rock Biotech
Limited (the “WFOE”) |
|
|
December 12, 2021 |
|
|
|
PRC |
|
|
|
100 |
% |
|
Investment holding |
| Beijing Burning Rock Biotech Co.,
Ltd. (the “Original WFOE”) |
|
|
June 13, 2014 |
|
|
|
PRC |
|
|
|
100 |
% |
|
Trading |
| Burning Rock Biotechnology (Shanghai) Co., Ltd. |
|
|
July 4, 2016 |
|
|
|
PRC |
|
|
|
100 |
% |
|
Research and development |
| Burning Rock Dx LLC |
|
|
August 28, 2019 |
|
|
|
United States |
|
|
|
100 |
% |
|
Cancer therapy selection test |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Burning Rock (Beijing) Biotechnology Co., Ltd. |
|
|
January 7, 2014 |
|
|
|
PRC |
|
|
|
Nil |
|
|
Holding |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Guangzhou Burning Rock Dx Co.,
Ltd. |
|
|
March 18, 2014 |
|
|
|
PRC |
|
|
|
Nil |
|
|
Cancer therapy selection test and
sales of reagent kits |
| Guangzhou Burning Rock Medical
Equipment Co., Ltd. |
|
|
January 6, 2015 |
|
|
|
PRC |
|
|
|
Nil |
|
|
Facilitation of laboratory equipment sales and sales of reagent kits |
|
| Summary of financial information of VIE and VIE's subsidiaries |
The following table sets forth the assets and liabilities of the VIE and subsidiaries of the VIE included in the Group’s consolidated balance sheets:
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
|
150,947 |
|
|
|
235,390 |
|
|
|
33,660 |
|
| Restricted cash |
|
|
20 |
|
|
|
20 |
|
|
|
3 |
|
| Accounts receivable (net of allowance of RMB45,590 and RMB58,895 (US$8,422) as of December 31, 2024 and 2025, respectively) |
|
|
151,971 |
|
|
|
168,097 |
|
|
|
24,037 |
|
| Contract assets (net of allowance of RMB61,856 and RMB65,651 (US$9,388) as of December 31, 2024 and 2025, respectively) |
|
|
13,855 |
|
|
|
12,301 |
|
|
|
1,759 |
|
| Inter-company receivables* |
|
|
605,656 |
|
|
|
517,689 |
|
|
|
74,029 |
|
| Inventories |
|
|
44,756 |
|
|
|
41,863 |
|
|
|
5,987 |
|
| Contract costs |
|
|
8,862 |
|
|
|
4,177 |
|
|
|
597 |
|
| Prepayments and other current assets |
|
|
13,737 |
|
|
|
7,915 |
|
|
|
1,133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total current assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Property and equipment, net |
|
|
19,656 |
|
|
|
17,205 |
|
|
|
2,461 |
|
| Intangible assets, net |
|
|
224 |
|
|
|
150 |
|
|
|
22 |
|
| |
|
|
5,353 |
|
|
|
4,450 |
|
|
|
636 |
|
| |
|
|
41,985 |
|
|
|
25,661 |
|
|
|
3,669 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TOTAL ASSETS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accounts payable |
|
|
30,408 |
|
|
|
39,283 |
|
|
|
5,617 |
|
| Deferred revenue |
|
|
110,652 |
|
|
|
100,766 |
|
|
|
14,409 |
|
| Inter-company payables* |
|
|
1,768,322 |
|
|
|
1,653,528 |
|
|
|
236,451 |
|
| Accrued liabilities and other current liabilities |
|
|
61,212 |
|
|
|
58,391 |
|
|
|
8,350 |
|
| Customer deposits |
|
|
592 |
|
|
|
592 |
|
|
|
85 |
|
| Current portion of operating lease liabilities |
|
|
13,832 |
|
|
|
13,129 |
|
|
|
1,877 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total current liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other non-current liabilities |
|
|
10,171 |
|
|
|
11,731 |
|
|
|
1,677 |
|
Non-current portion of operating lease liabilities |
|
|
26,669 |
|
|
|
12,956 |
|
|
|
1,853 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total non-current liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TOTAL LIABILITIES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * |
Inter-company receivables/payables represent balances of VIE and subsidiaries of the VIE due from/to the Company and the Group’s consolidated subsidiaries. |
|